Bristol-Myers Squibb Company (NYSE:BMY) dropped slightly amid mild profit booking and the last known price was $72.22 per share. The price decreased by -0.43 points or -0.59% which made the investors to buy on weakness. For the latest trading session, the net money flow was recorded at $112.61 million. The total upticks were valued at $146.98 million and the total downticks aggregated to $34.38 million, thereby putting the up/down ratio at 4.28,. The shares have seen a change in the share price of -0.92% on a weekly basis.In a big block trade which occurred today, the total uptick value was $115.06 million and the total downtick value was $1.73, resulting in an up/down ratio of 66.67. The net money flow for the block trade was calculated to be $113.34 million.
Currently the company Insiders own 0.24% of Bristol-Myers Squibb Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -15.67% . Institutional Investors own 74.66% of Bristol-Myers Squibb Company shares. During last six month period, the net percent change held by insiders has seen a change of -0.7%. On the companys insider trading activities,The officer (EVP & Chief Financial Officer) of Bristol Myers Squibb Co, Bancroft Charles A sold 30,201 shares at $70.79 on May 20, 2016. The Insider selling transaction had a total value worth of $2,137,929. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Bristol-Myers Squibb Company (NYSE:BMY) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.43 points or 0.59% at $72.22 with 4,726,820 shares getting traded. Post opening the session at $72.67, the shares hit an intraday low of $72 and an intraday high of $73.17 and the price was in this range throughout the day. The company has a market cap of $120,557 million and the number of outstanding shares have been calculated to be 1,669,307,300 shares. The 52-week high of Bristol-Myers Squibb Company (NYSE:BMY) is $75.12 and the 52-week low is $51.82.
Many analysts have stated their opinion on the company shares. Credit Suisse maintains their rating on the shares of Bristol-Myers Squibb Company (NYSE:BMY). The current rating of the shares is Outperform. Equity Analysts at the Firm raises the price target to $79 per share from $75 per share. The rating by the firm was issued on May 9, 2016.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.